The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib, is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with…
Drug Hunter > Molecules > pemigatinib
become a member to continue reading
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.
- Stay up-to-date and save more time with exclusive members-only content
- On-board new team members with educational content and case studies
- Generate ideas and discussion with easy-to-read slide decks
- Generate ideas and discussion with easy-to-read slide decks